The earnings call for Amgen Inc. provided a mixed bag of results and forward-looking statements. Here are the key points:

1. **Financial Performance:**
   - Revenue decreased by 2% year-over-year in 2009, primarily due to a stronger dollar and reduced wholesaler inventory.
   - Adjusted EPS was $4.91, an 8% increase compared to 2008.
   - Operating expenses increased due to higher R&D and SG&A expenses, particularly related to Prolia and the Array BioPharma agreement.

2. **Product Performance:**
   - Aranesp sales declined by 20% in the U.S. due to label changes and inventory fluctuations.
   - EPOGEN grew by 9% in the fourth quarter of 2009.
   - Neulasta and NEUPOGEN combined grew by 2% in the fourth quarter of 2009.
   - ENBREL sales were essentially flat.
   - Sensipar sales grew by 12%.
   - Vectibix sales grew by 43%.

3. **Pipeline and Regulatory:**
   - Prolia received a positive opinion from the CHNP for the approval to reduce fracture risk in women with postmenopausal osteoporosis at high risk for fracture and in men undergoing treatment for prostate cancer with androgen deprivation therapy.
   - Denosumab received positive data in reducing the risk of skeletal-related events in patients with metastatic bone disease.
   - Vectibix showed positive results in combination with chemotherapy for metastatic colorectal cancer.
   - The TREAT outcome study provided important information on the benefits and risks of Aranesp therapy.

4. **Guidance for 2010:**
   - Revenue is expected to be in the range of $15.1 billion to $15.5 billion.
   - Adjusted EPS is expected to be in the range of $5.05 to $5.25.
   - Tax rate is expected to be in the 20% to 21% range.
   - Capital expenditures are expected to be in the range of $600 million.

**Short-Term Impact on Stock Price:**
Given the mixed financial performance and the uncertainty around regulatory approvals for Prolia, the stock is likely to face some volatility in the short term. However, the strong pipeline and positive data from ongoing studies provide a long-term growth outlook. The stock may experience some downward pressure due to the reduced guidance and uncertainty around regulatory approvals, but it is also positioned to benefit from any positive developments in the pipeline.

**Rating:** -1